Oruka Therapeutics, Inc. - Common Stock ORKA 深 滬
已收盤 08-08 16:00:00 美东时间
13.09
-0.580
-4.24%
華盛通- 最 高13.90
- 今 開13.80
- 成交量 7.15万股
- 最 低 12.89
- 昨 收 13.67
- 總市值 4.90亿
- 52周最高 32.964
- 市盈率 靜 --
- 換手率 0.19%
- 52周最低 5.485
- 委 比 14.14%
- 總股本 3744.05万
- 歷史最高 5922.804
- 量 比 0.49
- 振 幅 7.39%
- 歷史最低 -0.636
- 每 手 1
- 風險率 6.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vertex reiterates $11.85B–$12B 2025 revenue guidance while boosting JOURNAVX commercial investment
Earnings Call Insights: Vertex Pharmaceuticals (VRTX) Q2 2025 Management View CEO Reshma Kewalramani highlighted "very strong performance across the board, growing and diversifying revenue with multip...
08-05 08:14
HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $45 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $45 price target.
07-23 18:30
Oriental Rise Receives Nasdaq Notification Regarding Minimum Bid-Price Requirement
Oriental Rise Holdings Limited received a notice from Nasdaq on June 30, 2025, regarding non-compliance with the minimum bid-price requirement due to its closing bid price being below US $1.00 for 30 consecutive business days. The company has 180 days until December 29, 2025, to regain compliance, which can be extended if certain conditions are met. Oriental Rise is actively evaluating options to address the issue and maintain its listing on Nasd...
07-07 19:05
Oruka Therapeutics announces COO appointment
Oruka Therapeutics (NASDAQ:ORKA) has promoted Laura Sandler to chief operating officer. Sandler joined Oruka in 2024 as SVP of Operations and has over 20 years of experience in biopharma leadership. S...
07-02 04:13
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
Oruka Therapeutics announced the promotion of Laura Sandler to Chief Operating Officer. With over 20 years of biopharmaceutical experience, Sandler has played a key role in advancing the company’s programs from preclinical stages to clinical trials. She previously served as SVP of Operations at Oruka and led the development of exa-cel at CRISPR Therapeutics, the first CRISPR-based medicine to gain regulatory approval. Oruka is focused on developi...
07-01 20:01
高盛Q1押注指数狂潮！标普500ET坐上重仓“头把交椅”
根据美国证券交易委员会(SEC)披露，高盛(GS.US)递交了截至2025年3月31日的第一季度持仓报告(13F)。 据统计，高盛第一季度持仓总市值为6200亿...
05-16 19:21
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $40 Price Target
Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $40 price target.
05-15 22:55
Oruka Therapeutics Q1 EPS $(0.40) Beats $(0.52) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.52) by 23.08 percent. This is a 81.9 percent increase over losses of $(2.21) per share from
05-15 04:43
开山股份：公司旗下成员公司KSOH得到匈牙利独家地热勘探权
开山股份（300257）公告称，2023年5月，公司旗下成员公司KS ORKA Hungary Kft参加了匈牙利能源部矿业管理局组织的申请地热勘探区域活动。近日，该局致函KSOH，通知其得到了注册编号为SZTFH-BANYASZ/692-6/2025的地热勘探许可证，该许可证将面积为171平方公里、深度250米至3500米的地热区块独家授予KSOH进行地热勘探）。
04-10 10:01
